Novo Nordisk
NVO
About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 78,387
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1% more repeat investments, than reductions
Existing positions increased: 569 | Existing positions reduced: 562
0% more funds holding in top 10
Funds holding in top 10: 24 [Q1] → 24 (+0) [Q2]
0.47% less ownership
Funds ownership: 9.54% [Q1] → 9.07% (-0.47%) [Q2]
3% less funds holding
Funds holding: 1,508 [Q1] → 1,460 (-48) [Q2]
7% less capital invested
Capital invested by funds: $22.9B [Q1] → $21.2B (-$1.69B) [Q2]
12% less first-time investments, than exits
New positions opened: 138 | Existing positions closed: 157
30% less call options, than puts
Call options by funds: $1.14B | Put options by funds: $1.63B
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
TD Cowen
Michael Nedelcovych
|
$70
|
Buy
Maintained
|
19 Aug 2025 |
Financial journalist opinion
Based on 244 articles about NVO published over the past 30 days
